News of Note—GlaxoSmithKline's Shingrix, Seqirus expansion and more

In this week's News of Note, GSK touted new Shingrix data.

Here's some other vaccine news of note for the week.

> A phase 3 study showed that GlaxoSmithKline's Shingrix is effective for adults 18 and older after they have undergone an autologous hematopoietic stem cell transplant. Release

> Seqirus is investing $9 million to expand its North Carolina flu vaccine manufacturing plant. NCBiotech story

> Aduro is giving up on its most advanced cancer vaccine program. Endpoints News story

> Formerly a subsidiary of Valneva, Maryland's Intercell changed its name to Valneva USA and is taking over marketing and distribution rights for Japanese encephalitis vaccine Ixiaro. Release